Pharming Group (NASDAQ:PHAR - Get Free Report) shares shot up 10.3% on Monday . The stock traded as high as $8.41 and last traded at $8.49. 5,462 shares changed hands during mid-day trading, a decline of 14% from the average session volume of 6,343 shares. The stock had previously closed at $7.69.
Wall Street Analysts Forecast Growth
PHAR has been the subject of several research analyst reports. Oppenheimer boosted their price objective on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th.
Check Out Our Latest Research Report on PHAR
Pharming Group Stock Performance
The company has a 50-day moving average price of $8.57 and a 200-day moving average price of $8.70. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $547.65 million, a price-to-earnings ratio of -30.96 and a beta of -0.08.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. As a group, equities research analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by hedge funds and other institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
